A successful experience of using recombinant human coagulation factor Ⅶ a for treatment of a patient with pernicious placenta previa and massive postpartum hemorrhage
10.3969/j.issn.1008-9691.2017.05.023
- VernacularTitle:利用重组人凝血因子Ⅶa成功救治凶险型前置胎盘合并产后大出血的体会
- Author:
Zhengkuan SHEN
1
,
2
;
562200 贵州兴义,贵州省贞丰县人民医院
;
Liang LI
;
Feng SHEN
;
Cui WANG
;
Wei LI
;
Wenyi YU
Author Information
1. 550004 贵州贵阳,贵州医科大学附属医院重症医学科
2. 562200 贵州兴义,贵州省贞丰县人民医院
- Keywords:
Recombinant human coagulation factor Ⅶa;
Pernicious placenta previa;
Massive postpartum hemorrhage
- From:
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
2017;24(5):542-544
- CountryChina
- Language:Chinese
-
Abstract:
Massive postpartum hemorrhage is one of the most severe complications of pregnant women during deliveries, especially, on the basis of a scarred uterus with placenta previa and placenta implantation, the risk of occurrence of massive hemorrhage after delivery will be obviously increased. The recombinant human coagulation factorⅦa (rFⅦa) can be used to significantly reduce the incidence of delutional coagulopathy and the necessary amount of blood products in patients after major abdominal surgery. One patient with massive postpartum hemorrhage resulted from scarred uterus with placenta previa and previa accreta was administered into Guizhou Medical University Affiliated Hospital, whose hemorrhage was successfully stopped by using rFⅦa in case of surgical indication being excluded. It is suggested that rFⅦa can be regarded as an effective drug for postpartum hemorrhage on the basis of indication being strictly controlled.
